Anti-Cancer Drugs — Part 1

Correct Answer

B — Ribonucleotide reductase inhibitor

Rationale

Hydroxyurea is classified as a ribonucleotide reductase inhibitor. It scavenges the stable tyrosyl radical in the R2 subunit of ribonucleotide reductase, the rate-limiting enzyme that converts ribonucleoside diphosphates to deoxyribonucleoside diphosphates in de novo deoxyribonucleic acid synthesis. Dihydrofolate reductase inhibitors (methotrexate, pemetrexed) target folate metabolism. Topoisomerase II inhibitors (etoposide, anthracyclines) stabilize deoxyribonucleic acid strand-break intermediates. Alkylating agents (cyclophosphamide, cisplatin) form covalent deoxyribonucleic acid adducts. Hydroxyurea acts on none of these targets.

Correct Answer

D — Polyethylene glycol-conjugated asparaginase

Rationale

Pegaspargase is classified as a polyethylene glycol-conjugated asparaginase. It is native Escherichia coli-derived asparaginase to which polyethylene glycol chains have been covalently attached, reducing immunogenicity and extending the plasma half-life from approximately 1.2 days to approximately 5.5 to 7 days, allowing less frequent dosing in acute lymphoblastic leukemia protocols. Native Escherichia coli-derived asparaginase is the unmodified parent preparation. Erwinia chrysanthemi-derived asparaginase (crisantaspase) is a structurally distinct asparaginase used when hypersensitivity to Escherichia coli-based preparations precludes pegaspargase. Pegylated granulocyte colony-stimulating factor (pegfilgrastim) is an entirely different drug class used for neutropenia prevention.

Correct Answer

A — Second-generation immunomodulatory drug

Rationale

Lenalidomide is classified as a second-generation immunomodulatory drug and a thalidomide analog. Immunomodulatory drugs bind to cereblon, an E3 ubiquitin ligase adaptor, and direct proteasomal degradation of specific transcription factors critical for myeloma cell survival. Lenalidomide has substantially greater potency for this mechanism than thalidomide (the first-generation drug) and less neurotoxicity. Proteasome inhibitors (bortezomib, carfilzomib) block the 26S proteasome directly and are a distinct drug class. Histone deacetylase inhibitors (vorinostat, romidepsin) are epigenetic agents. Anti-CD38 monoclonal antibodies (daratumumab) target a surface antigen on myeloma cells.

Correct Answer

C — Serotonin-norepinephrine reuptake inhibitor

Rationale

Duloxetine is classified as a serotonin-norepinephrine reuptake inhibitor. It is the only pharmacological agent with Level I evidence from a randomized controlled trial demonstrating reduction in chemotherapy-induced peripheral neuropathy pain and sensory symptoms. Its analgesic mechanism involves enhanced descending pain inhibition through increased serotonergic and noradrenergic tone in spinal dorsal horn circuits. Opioid analgesics address pain without modifying neuropathic mechanisms and are not the preferred agent for chemotherapy-induced peripheral neuropathy. Gabapentinoids (gabapentin, pregabalin) modulate voltage-gated calcium channels but lack randomized controlled trial evidence for chemotherapy-induced peripheral neuropathy. Tricyclic antidepressants are used for neuropathic pain generally but also lack Level I evidence in this specific setting.

Correct Answer

B — Third-generation immunomodulatory drug

Rationale

Pomalidomide is classified as a third-generation immunomodulatory drug. The immunomodulatory drug class progresses in potency across generations: thalidomide is the first-generation agent; lenalidomide is the second-generation agent with greater cereblon-mediated Ikaros and Aiolos degradation potency and improved tolerability compared with thalidomide; pomalidomide is the third-generation agent with the highest potency for cereblon-mediated Ikaros and Aiolos degradation and retained activity in lenalidomide-refractory disease. Pomalidomide is approved for relapsed or refractory multiple myeloma after at least two prior therapies. It is not a proteasome inhibitor — that is a separate drug class including bortezomib and carfilzomib.

Correct Answer

D — Erwinia asparaginase, which is derived from a different bacterial species and avoids cross-reactive antibodies against Escherichia coli-based preparations

Rationale

When a patient develops hypersensitivity to pegaspargase or native Escherichia coli-derived asparaginase, the cross-reactive antibodies generated typically inactivate both Escherichia coli-based formulations. Erwinia asparaginase (crisantaspase, derived from Erwinia chrysanthemi) is structurally distinct from Escherichia coli-derived asparaginase and is not recognized by the cross-reactive antibodies, allowing continuation of asparaginase-based therapy. Higher doses of pegaspargase with premedication do not overcome established immunological hypersensitivity. Native Escherichia coli-derived asparaginase shares the same immunogenic epitopes as pegaspargase and would elicit the same reaction. Filgrastim is a granulocyte colony-stimulating factor with no role in asparagine supplementation.

Correct Answer

A — Hydroxyurea increases fetal hemoglobin production in erythroid precursors; fetal hemoglobin does not participate in hemoglobin S polymerization, so higher fetal hemoglobin levels reduce the proportion of hemoglobin S available for sickling and decrease vaso-occlusive crisis frequency

Rationale

Hydroxyurea reduces vaso-occlusive crises by increasing fetal hemoglobin production in erythroid precursors. Fetal hemoglobin contains gamma-globin chains rather than beta-globin chains and does not participate in the polymerization of deoxyhemoglobin S that causes red blood cell sickling. By raising fetal hemoglobin levels, hydroxyurea dilutes the intracellular concentration of hemoglobin S, reduces the fraction of hemoglobin available for polymerization, and decreases crisis frequency. This effect on fetal hemoglobin — mediated through reactivation of gamma-globin gene expression in erythroid precursors — is the primary clinical mechanism for sickle cell disease, distinct from hydroxyurea's ribonucleotide reductase inhibitory mechanism used in oncology. Hydroxyurea does not chelate intracellular iron, does not reduce the number of sickle cells by limiting proliferation, and does not intercalate into hemoglobin polymer structures.

Correct Answer

C — Acute lymphoblastic leukemia blasts, particularly T-cell blasts, express very low levels of asparagine synthetase and depend on exogenous asparagine for protein synthesis; depletion of circulating asparagine by asparaginase starves them of this essential substrate, inducing endoplasmic reticulum stress and apoptosis

Rationale

The selectivity of asparaginase exploits a specific metabolic vulnerability of certain leukemic blast populations. Most normal cells synthesize asparagine endogenously from aspartate and glutamine through the enzyme asparagine synthetase, making them relatively independent of circulating asparagine. Certain acute lymphoblastic leukemia blast populations, particularly those of T-cell lineage, express very low or absent levels of asparagine synthetase and therefore depend on exogenous asparagine from the circulation for protein synthesis. When asparaginase depletes circulating asparagine by hydrolyzing it to aspartate and ammonia, asparagine synthetase-deficient blasts cannot replenish their intracellular asparagine supply, leading to protein synthesis failure, endoplasmic reticulum stress, and apoptosis. The selectivity is based on differential asparagine synthetase expression, not on selective drug uptake, prodrug activation, or any blast-specific transporter.

Correct Answer

B — Thalidomide and its analogs bind to cereblon, an intracellular protein, and redirect its activity to degrade transcription factors required for myeloma cell survival and proliferation, causing myeloma cell death

Rationale

Thalidomide and its analogs — lenalidomide and pomalidomide — are immunomodulatory drugs that exert anti-myeloma activity by binding cereblon, a protein that normally participates in controlling which other proteins are marked for degradation inside cells. When thalidomide binds cereblon, it changes cereblon's target specificity so that transcription factors essential for myeloma cell survival are redirected into the degradation pathway and destroyed. Without these survival factors, myeloma cells undergo apoptosis. This cereblon-mediated targeted protein degradation is the primary anti-myeloma mechanism of the immunomodulatory drug class. Thalidomide does not inhibit the proteasome directly — proteasome inhibition is the mechanism of bortezomib and carfilzomib. Thalidomide does not intercalate into genetic material. Anti-angiogenic activity through vascular endothelial growth factor receptor inhibition has been proposed as a contributing mechanism but cereblon-mediated targeted protein degradation remains the dominant anti-myeloma activity of this drug class.

Correct Answer

D — Thalidomide is absolutely contraindicated in pregnancy because even a single dose during organogenesis causes severe limb malformations; the Thalomid REMS requires confirmed negative pregnancy testing, two simultaneous forms of contraception throughout therapy, and condom use in male patients because thalidomide is present in semen

Rationale

Thalidomide caused one of the most catastrophic pharmaceutical teratogenic disasters in history, producing approximately 10,000 children with severe phocomelia (limb reduction defects) when administered to pregnant women for morning sickness in the late 1950s and early 1960s. The teratogenicity is so severe that even a single dose during the critical developmental window of organogenesis (weeks 3 to 8 post-conception) can cause major structural malformations. The Thalomid Risk Evaluation and Mitigation Strategy (REMS) program mandates: confirmed negative pregnancy test within 10 to 14 days before starting therapy for women of childbearing potential, two simultaneous forms of contraception throughout therapy and for 4 weeks after the last dose, monthly pregnancy testing in women of childbearing potential, and condom use in male patients throughout therapy because thalidomide is present in semen and could expose a partner during intercourse. These are federally mandated conditions of prescribing. The cardiac, hepatic, and renal monitoring options are not the basis of the Thalomid REMS requirements.

Correct Answer

A — Lenalidomide combined with dexamethasone markedly increases the risk of venous thromboembolism compared to either agent alone; the combination creates a prothrombotic state through mechanisms including increased platelet activation and altered coagulation factor expression, requiring prophylactic anticoagulation throughout therapy

Rationale

Lenalidomide substantially increases the risk of venous thromboembolism, and this risk is amplified further when lenalidomide is combined with dexamethasone or doxorubicin. The exact mechanisms are not fully characterized but involve increased platelet activation, upregulation of procoagulant factors, and altered endothelial function. The clinical consequence is a clinically significant incidence of deep vein thrombosis and pulmonary embolism — high enough that prophylactic anticoagulation is mandatory for all patients. The appropriate thromboprophylaxis intensity depends on patient risk factors: aspirin for low-risk patients, low molecular weight heparin or warfarin for high-risk patients. Lenalidomide does not inhibit fibrinogen synthesis, dexamethasone does not cause disseminated intravascular coagulation through tumor lysis at induction doses, and lenalidomide is not converted to a thromboxane analog.

Correct Answer

C — Paroxetine and fluoxetine are potent cytochrome P450 2D6 inhibitors; cytochrome P450 2D6 converts tamoxifen to the active metabolite endoxifen, and inhibition reduces endoxifen plasma concentrations by 65 to 75%, potentially reducing long-term tamoxifen efficacy

Rationale

Tamoxifen is a prodrug that undergoes metabolic activation to endoxifen, its pharmacologically active form, via cytochrome P450 2D6-mediated hydroxylation. Endoxifen has approximately 100-fold greater affinity for the estrogen receptor than tamoxifen and is responsible for the majority of tamoxifen's anti-estrogenic therapeutic effect in hormone receptor-positive breast cancer. Paroxetine and fluoxetine are among the most potent cytochrome P450 2D6 inhibitors in clinical use. When co-administered with tamoxifen, they reduce endoxifen plasma concentrations by 65 to 75%, substantially impairing the pharmacological activation on which tamoxifen's long-term benefit depends. For patients on tamoxifen who require antidepressant therapy, drugs with low cytochrome P450 2D6 inhibitory activity — venlafaxine, citalopram, or escitalopram — are preferred. The mechanism involves cytochrome P450 2D6, not cytochrome P450 3A4, and is inhibition, not induction. Paroxetine and fluoxetine do not bind to the estrogen receptor.

Correct Answer

B — Alkylating agent-related secondary leukemia has longer latency (5 to 10 years), typically presents after a myelodysplastic syndrome phase, and shows chromosomal losses; topoisomerase II inhibitor-related secondary leukemia has shorter latency (1 to 3 years), presents de novo without a myelodysplastic phase, and shows balanced chromosomal translocations

Rationale

Treatment-related myeloid neoplasms caused by alkylating agents and topoisomerase II inhibitors have characteristic and distinguishable clinical patterns. Alkylating agent-related secondary leukemia has a long latency — typically 5 to 10 years — and almost always presents after a myelodysplastic syndrome phase with cytopenias and dysplastic marrow changes. The cytogenetic profile shows chromosomal losses, particularly of chromosomes 5 and 7. Topoisomerase II inhibitor-related secondary leukemia — as seen in the etoposide-treated patient — has a much shorter latency of 1 to 3 years and arises de novo without a preceding myelodysplastic syndrome phase. Its cytogenetics show balanced translocations rather than chromosomal losses. Recognizing these two patterns is clinically important because the latency, clinical presentation, and cytogenetics together allow identification of the likely causative drug class even years after treatment. These are not the same disease process presenting at different rates, and the difference in latency does not reflect which cell population is targeted.

Correct Answer

D — All cytotoxic chemotherapy is contraindicated during the first trimester because organogenesis (weeks 3 to 8 post-conception) is the critical window for major structural malformations; after the first trimester, many regimens such as CHOP can be administered with acceptable fetal outcomes, though antimetabolites remain relatively contraindicated throughout pregnancy

Rationale

The pharmacological rationale for chemotherapy timing in pregnancy is governed by embryological vulnerability. Organogenesis — the period during which fetal organ systems develop from undifferentiated cells into their final structural form — occurs primarily between weeks 3 and 8 post-conception, which corresponds approximately to weeks 5 through 10 of gestational age. During this window, virtually all cytotoxic chemotherapy is contraindicated because disruption of rapidly dividing, differentiating cells produces major structural malformations. At week 10 of pregnancy (approximately week 8 post-conception), this patient is at the very end of the critical organogenesis window. After the first trimester, fetal organ development is largely complete and chemotherapy is far less likely to cause major structural defects, though risks of growth restriction, premature delivery, and neonatal myelosuppression remain. Regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) with rituximab have been administered in the second and third trimesters with acceptable outcomes. Antimetabolites such as methotrexate and 5-fluorouracil remain relatively contraindicated throughout pregnancy because of their anti-folate mechanisms, which are particularly hazardous to the developing fetus at all gestational ages. The placenta does not act as a barrier to cytotoxic drugs, and first-trimester administration is not safe.

Correct Answer

B — No dose change is needed; macrocytosis is an expected pharmacodynamic response to hydroxyurea reflecting increased fetal hemoglobin production and altered red blood cell maturation, and it does not indicate toxicity or require dose reduction when blood counts are otherwise stable

Rationale

Macrocytosis is a consistent and expected pharmacodynamic effect of hydroxyurea in sickle cell disease and is considered a marker that the drug is working rather than a sign of harm. Hydroxyurea reactivates gamma-globin gene expression, increasing fetal hemoglobin production. Red blood cells that contain fetal hemoglobin are larger than those containing predominantly hemoglobin S, and hydroxyurea also alters the kinetics of erythroid maturation through its ribonucleotide reductase inhibition. The resulting increase in mean corpuscular volume to the range of 100 to 130 femtoliters is routinely observed in patients responding to hydroxyurea and does not require dose reduction, drug interruption, or investigation for vitamin B12 deficiency unless other findings suggest a coexisting deficiency. The relevant toxicity signals that do require dose adjustment or interruption are myelosuppression (low absolute neutrophil count, thrombocytopenia, or anemia), not macrocytosis itself. Hydroxyurea does not cause leukemic transformation of erythroid precursors.

Correct Answer

A — Negative pregnancy test within 10 to 14 days, confirmation of two simultaneous contraceptive methods, and enrollment in the Thalomid Risk Evaluation and Mitigation Strategy program — because even a single dose during organogenesis causes severe limb malformations, requiring federally mandated safety verification before dispensing

Rationale

Thalidomide's catastrophic teratogenicity — which caused thousands of cases of severe limb reduction defects (phocomelia) when used for morning sickness in the late 1950s and early 1960s — is the reason for the Risk Evaluation and Mitigation Strategy program that governs its current clinical use. A single dose during the critical window of limb organogenesis is sufficient to cause malformation. For any patient of reproductive potential, the program requires a documented negative pregnancy test within 10 to 14 days before the first dose, enrollment of both the prescriber and patient in the registry, and confirmation that the patient is using two simultaneous and reliable contraceptive methods. Weekly pregnancy testing is required during treatment for women with regular menstrual cycles. These requirements apply regardless of the clinical indication. The Risk Evaluation and Mitigation Strategy does not require histological disease confirmation, does not mandate cardiac or renal baseline testing, and does not require prospective nerve conduction studies — though clinicians monitor for neuropathy and thrombosis as standard practice.

Correct Answer

D — This patient has multiple risk factors (obesity, hypertension, immunomodulatory drug plus dexamethasone combination) that place him in the high-risk category; low molecular weight heparin or warfarin is the appropriate thromboprophylaxis, because the lenalidomide-dexamethasone combination markedly increases venous thromboembolism risk and high-risk patients require more intensive prophylaxis than aspirin alone

Rationale

Lenalidomide combined with dexamethasone substantially increases the risk of venous thromboembolism through mechanisms including platelet activation, upregulation of procoagulant factors, and endothelial dysfunction. This prothrombotic risk is further amplified by patient-specific factors. Risk stratification guides the intensity of thromboprophylaxis: low-risk patients (lenalidomide plus dexamethasone, no additional risk factors) may receive aspirin 81 mg daily; high-risk patients — defined as those with two or more individual risk factors (including obesity, history of thrombosis, immobility, inherited thrombophilia, cardiac disease, diabetes, hypertension, or renal impairment) or any myeloma-related risk factor (including combination with doxorubicin or erythropoietin-stimulating agents) — require low molecular weight heparin or warfarin. This patient has at least two individual risk factors (obesity, hypertension) in addition to the lenalidomide-dexamethasone combination, placing him in the high-risk category where aspirin alone is insufficient. Thromboprophylaxis is mandatory, not optional. Continuous intravenous heparin at therapeutic doses is not the standard prophylactic approach for immunomodulatory drug-related thromboembolism prevention.

Correct Answer

C — Doxorubicin dose should be reduced to 50% (30 mg per square meter) because doxorubicin undergoes extensive hepatic metabolism and biliary excretion; bilirubin in the range of 1.2 to 3.0 mg per deciliter indicates impaired hepatic clearance that causes doxorubicin to accumulate to concentrations producing excess cardiotoxicity and myelosuppression

Rationale

Doxorubicin undergoes extensive hepatic metabolism and biliary excretion as its primary elimination pathway. When hepatic function is impaired and biliary clearance is reduced, doxorubicin and its active metabolite doxorubicinol accumulate to higher plasma and tissue concentrations than would be achieved with normal hepatic function at the same administered dose. The excess drug exposure increases the risk of cumulative cardiotoxicity and myelosuppression at doses that would be safe in patients with normal hepatic clearance. Standard bilirubin-based dose reduction guidelines for doxorubicin are: bilirubin 1.2 to 3.0 mg per deciliter, give 50% of the dose; bilirubin above 3.0 mg per deciliter, give 25% of the dose. With a bilirubin of 2.4 mg per deciliter, this patient falls in the first category and requires a 50% dose reduction to 30 mg per square meter. Doxorubicin is not primarily renally excreted — hepatic metabolism is the dominant elimination pathway — so renal function does not determine this adjustment. A 25% dose would apply only if bilirubin exceeded 3.0 mg per deciliter.